H. Pylori
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 15, 2003; 9(11): 2501-2504
Published online Nov 15, 2003. doi: 10.3748/wjg.v9.i11.2501
Detection of serum anti-Helicobacter pylori immunoglobulin G in patients with different digestive malignant tumors
Ke-Xia Wang, Xue-Feng Wang, Jiang-Long Peng, Yu-Bao Cui, Jian Wang, Chao-Pin Li
Ke-Xia Wang, Xue-Feng Wang, Jiang-Long Peng, Yu-Bao Cui, Jian Wang, Chao-Pin Li, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, Anhui Province, China
Author contributions: All authors contributed equally to the work.
Supported by Natural Science Foundation of the Education Department of Anhui Province, China, No.2003kj111
Correspondence to: Dr. Chao-Pin Li, Department of Etiology and immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, Anhui Province, China. cpli@aust.edu.cn
Telephone: +86-554-6658770 Fax: +86-554-6662469
Received: March 2, 2003
Revised: March 22, 2003
Accepted: June 4, 2003
Published online: November 15, 2003
Abstract

AIM: To investigate the seroprevalence of Helicobacter pylori infection in patients with different digestive malignant tumors.

METHODS: Enzyme linked immunosorbent assay (ELISA) was used to detect serum anti-Helicobacter pylori IgG antibody in 374 patients with different digestive malignant tumors and 310 healthy subjects (normal control group).

RESULTS: The seroprevalence of Helicobacter pylori infection was 61.50% (230/374) and 46.77% (145/310), respectively, in patients with digestive tumors and normal controls (P < 0.05). The seroprevalence was 52.38% (33/63), 86.60% (84/97), 83.14% (84/101), 45.24 (19/42), 51.13% (18/35) and 44.44% (16/36), respectively in patients with carcinomas of esophagus, stomach, duodenum, rectum, colon and liver (P < 0.01). In patients with intestinal and diffuse type gastric cancers, the seroprevalence was 93.75% (60/64) and 72.73% (24/33), respectively (P < 0.05). In patients with gastric antral and cardiac cancers, the seroprevalence was 96.43% (54/56) and 73.17% (30/41), respectively (P < 0.05). In patients with ulcerous and proliferous type duodenal cancers, the seroprevalence of H. pylori infection was 91.04% (61/67) and 52.27% (23/44), respectively (P < 0.05). In patients with duodenal bulb and descending cancers, the seroprevalence was 94.20% (65/69) and 45.20% (19/42), respectively (P < 0.05).

CONCLUSION: H. pylori infection is associated with occurrence and development of gastric and duodenal carcinomas. Furthermore, it is also associated with histological type and locations of gastric and duodenal carcinomas.

Keywords: $[Keywords]